Table 1.
Demographic and clinicopathological characteristics of patients at baseline
| Features | Patients, N (%) |
|---|---|
| Age/median (range) | 41.5 (32-69) yrs |
| Gender | 5 (83.0) |
| Male | |
| Performance status | |
| 0 | 2 (33.3) |
| 1 | 4 (66.7) |
| Tumor location | |
| Body | 3 (50.0) |
| Antrum | 2 (33.3) |
| Fundus | 1 (16.7) |
| Pathological type | |
| Adenocarcinoma | 5 (83.3) |
| Lymphoepithelioma-like carcinoma | 1 (16.7) |
| Lauren classification | |
| Diffuse | 1 (16.7) |
| Intestine | 2 (33.3) |
| Mixed | 3 (50.0) |
| Prior surgery | |
| No | 2 (33.3) |
| Radical surgery | 2 (33.3) |
| Palliative surgery | 2 (33.3) |
| Metastasis | |
| Synchronous | 5 (83.3) |
| Metachronous | 1 (16.7) |
| No. of metastatic sites | |
| 0-2 | 5 (83.3) |
| >2 | 1 (16.7) |
| Site of metastatic disease | |
| Liver | 1 (16.7) |
| Bone | 2 (33.3) |
| Peritoneum | 3 (50.0) |
| Lymph node | 4 (66.7) |
| Ascites | |
| No | 4 (66.7%) |
| Yes | 2 (33.3) |
| HER2 status, negative no. (%) | 6 (100) |
| ERBR, Positive no. (%) | 6 (100) |
| PD-L1 CPS (%) | |
| <1 | 5 (83.3) |
| 1-5 | 1 (16.7) |
| TMB (Mut/Mb) | |
| <10 | 3 (50.0) |
| ≥10 | 3 (50.5) |
| Previous treatment | |
| Platinum and fluorouracil | 6 (100) |
| Taxales | 5 (83.3) |
| Apatinib | 2 (33.3) |
| Ramucirumab | 1 (16.7) |